Related Experiment Videos
Low-dose cyclosporin nephrotoxicity in the rat
C J Ferguson1, C von Ruhland, D J Parry-Jones
1Department of Surgery, Cardiff Royal Infirmary, UK.
Summary
Cyclosporin (CsA) causes kidney damage (nephrotoxicity) in patients. This study developed a new animal model using clinically relevant CsA doses to better understand and treat this common side effect.
Area of Science:
- Nephrology
- Immunology
- Pharmacology
Background:
- Cyclosporin (CsA) is a vital immunosuppressant, but its use is limited by nephrotoxicity.
- Existing animal models for CsA nephrotoxicity often use non-clinical doses or administration routes.
- A need exists for a relevant animal model that reflects human clinical scenarios.
Purpose of the Study:
- To establish a novel animal model for cyclosporin (CsA) nephrotoxicity.
- To utilize clinically relevant CsA doses and administration schedules.
- To enable longitudinal assessment of CsA-induced renal functional and structural changes.
Main Methods:
- Administered varying doses of CsA intraperitoneally to animals.
- Measured glomerular filtration rate (GFR) and effective renal plasma flow (ERPF) using chromium EDTA and iodohippuran clearance.
- Conducted sequential measurements in individual animals.
- Performed detailed histological examination of kidney tissues.
Main Results:
- CsA doses as low as 5 mg/kg/day significantly impaired GFR.
- Doses of 7.5 mg/kg/day reduced ERPF, and 10 mg/kg/day or higher decreased filtration fraction.
- Histological analysis revealed tubular dilatation at CsA doses of 10 mg/kg/day and above.
Conclusions:
- This study successfully developed a relevant animal model for CsA nephrotoxicity.
- The model allows for longitudinal studies using clinically comparable CsA doses.
- This approach provides a foundation for future research mimicking clinical immunosuppression and its renal side effects.